- Home
- AKTX vs BEAT Comparison
AKTX vs BEAT Comparison
Compare AKTX & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- BEAT
- Stock Information
- Founded
- AKTX N/A
- BEAT 2015
- Country
- AKTX United States
- BEAT United States
- Employees
- AKTX N/A
- BEAT N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- BEAT Retail: Computer Software & Peripheral Equipment
- Sector
- AKTX Health Care
- BEAT Technology
- Exchange
- AKTX Nasdaq
- BEAT Nasdaq
- Market Cap
- AKTX 35.7M
- BEAT 37.7M
- IPO Year
- AKTX N/A
- BEAT 2021
- Fundamental
- Price
- AKTX $0.84
- BEAT $1.32
- Analyst Decision
- AKTX Strong Buy
- BEAT Buy
- Analyst Count
- AKTX 1
- BEAT 1
- Target Price
- AKTX $5.00
- BEAT $8.00
- AVG Volume (30 Days)
- AKTX 85.8K
- BEAT 121.4K
- Earning Date
- AKTX 08-13-2025
- BEAT 11-06-2025
- Dividend Yield
- AKTX N/A
- BEAT N/A
- EPS Growth
- AKTX N/A
- BEAT N/A
- EPS
- AKTX N/A
- BEAT N/A
- Revenue
- AKTX N/A
- BEAT N/A
- Revenue This Year
- AKTX N/A
- BEAT N/A
- Revenue Next Year
- AKTX N/A
- BEAT N/A
- P/E Ratio
- AKTX N/A
- BEAT N/A
- Revenue Growth
- AKTX N/A
- BEAT N/A
- 52 Week Low
- AKTX $0.57
- BEAT $0.91
- 52 Week High
- AKTX $3.85
- BEAT $3.48
- Technical
- Relative Strength Index (RSI)
- AKTX 44.86
- BEAT 56.53
- Support Level
- AKTX $0.57
- BEAT $1.34
- Resistance Level
- AKTX $1.01
- BEAT $1.54
- Average True Range (ATR)
- AKTX 0.07
- BEAT 0.11
- MACD
- AKTX -0.00
- BEAT 0.03
- Stochastic Oscillator
- AKTX 63.51
- BEAT 53.88
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.